TD Asset Management Inc. decreased its position in AtriCure, Inc. (NASDAQ:ATRC – Get Rating) by 27.5% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 57,817 shares of the medical device company's stock after selling 21,888 shares during the quarter. TD Asset Management Inc. owned 0.12% of AtriCure worth $3,797,000 as of its most recent SEC filing.
Several other hedge funds also recently made changes to their positions in ATRC. Pinebridge Investments L.P. acquired a new position in shares of AtriCure in the 4th quarter worth approximately $56,000. First Horizon Advisors Inc. lifted its holdings in shares of AtriCure by 80.5% in the 4th quarter. First Horizon Advisors Inc. now owns 1,496 shares of the medical device company's stock worth $103,000 after purchasing an additional 667 shares during the last quarter. Islay Capital Management LLC bought a new stake in shares of AtriCure in the 1st quarter worth approximately $117,000. Rockefeller Capital Management L.P. lifted its holdings in shares of AtriCure by 10.1% in the 4th quarter. Rockefeller Capital Management L.P. now owns 2,341 shares of the medical device company's stock worth $162,000 after purchasing an additional 215 shares during the last quarter. Finally, Ensign Peak Advisors Inc bought a new stake in shares of AtriCure in the 4th quarter worth approximately $203,000. Institutional investors and hedge funds own 95.36% of the company's stock.
Get AtriCure alerts:Analyst Upgrades and Downgrades
Several analysts recently issued reports on ATRC shares. Stifel Nicolaus cut their price target on AtriCure from $70.00 to $50.00 in a report on Monday, July 18th. StockNews.com downgraded AtriCure from a "hold" rating to a "sell" rating in a research note on Tuesday. Piper Sandler cut their target price on AtriCure from $90.00 to $55.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 3rd. Needham & Company LLC lifted their target price on AtriCure from $55.00 to $65.00 and gave the company a "buy" rating in a research note on Wednesday, August 3rd. Finally, BTIG Research cut their target price on AtriCure from $94.00 to $75.00 and set a "buy" rating on the stock in a research note on Friday, June 24th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company's stock. According to MarketBeat, AtriCure currently has a consensus rating of "Moderate Buy" and an average price target of $75.86.
AtriCure Trading Down 4.7 %
Shares of AtriCure stock opened at $47.04 on Friday. The business has a fifty day simple moving average of $45.69 and a 200-day simple moving average of $51.84. The firm has a market cap of $2.18 billion, a price-to-earnings ratio of 40.55 and a beta of 1.20. The company has a quick ratio of 2.93, a current ratio of 3.66 and a debt-to-equity ratio of 0.15. AtriCure, Inc. has a fifty-two week low of $32.83 and a fifty-two week high of $89.18.AtriCure (NASDAQ:ATRC – Get Rating) last announced its earnings results on Tuesday, August 2nd. The medical device company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.02). AtriCure had a negative return on equity of 11.47% and a net margin of 17.62%. During the same period last year, the business earned ($0.30) EPS. On average, equities analysts forecast that AtriCure, Inc. will post -1.09 EPS for the current fiscal year.
AtriCure Profile
(Get Rating)
AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation.
Recommended Stories
- Get a free copy of the StockNews.com research report on AtriCure (ATRC)
- Why This Dip in Advanced Auto Parts May be an Opportunity
- MarketBeat: Week in Review 8/22 – 8/26
- Institutional Buying Put A Bottom In Marvell Technology
- Dell Stock Retreats On Weaker Sales, Falls Into Value Terrirtory
- 3 Reasons Dollar General's Rally Has Legs
Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure, Inc. (NASDAQ:ATRC – Get Rating).
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.